Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease

ConditionParoxysmal Atrial Fibrillation

Trial statusNot yet recruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorAssiut University

About this trial

The aim of this study is to study synergistic effect of eplerenone as Selective aldosterone receptor antagonist with amiodarone compared with amiodarone only in reducing recurrence of atrial fibrillation in patient with structural heart disease

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

1-patients are currently on eplerenone or spironolactone 2-hyperkalemia 3-impaired renal function(if CrCl <50ml/min or serum creatinine>2 mg/dl) 4-patient on beta blocker and calcium channel blocker (non- dihydropyridine) 5-prosthetic valve 6-severe mitral stenosis 7-thyroid dysfunction 8-WPW 9-severe liver disease 10-persistent or permanent AF 11-pregnancy or breast feeding 12-LV EF<50% 13-known hypersensitivity or drug reaction to amiodarone 14-acute coronary syndrome 15-refusal of consent

Trial design

Design model

Parallel

Treatments tested in this trial

Eplerenone
Drug
Amiodarone vs eplerenone in AF

Treatment groups

100 Participants

are divided into 2 treatment groups

Group A: Amiodarone as comparisonActive comparator 1 intervention

Group B: Eplerenone plus amiodaroneExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Role of eplerenone in reducing recurrence of atrial fibrillation in patient with structural heart disease

decrease recurrence of paroxysmal AF in patient of structural heart disease

Time frame

Baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: